Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

Syros Pharmaceuticals (SYRS) announced that its Board of Directors has approved and the company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market and the deregistration of its common stock in order to terminate and suspend the company’s reporting obligations under the Securities and Exchange Act of 1934, as amended. The company notified Nasdaq of its intention to voluntarily delist its shares of common stock from the Nasdaq Global Select Market. The company intends to file a Form 25 with the SEC to effect the delisting and deregistration of its common stock on or about March 10, and the delisting is expected to become effective on or about March 20.